Antibody Drugs In-Vivo RNA 
Drug Discovery World
MAY 17, 2024
From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields. News round-up for 13-16 May by DDW Senior Digital Content Editor Diana Spencer.
Drug Discovery World
MARCH 26, 2024
For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. In vivo, METTL1 inhibitors induce tumour growth inhibition in both immune-deficient and immune-competent mouse strains. We were there to present the latest findings from our research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 15, 2024
To support this goal, Heidelberg Pharma presented safety and first efficacy data from the Phase I/IIa clinical trial with lead ATAC product candidate HDP-101 as well as preclinical data on other drug candidates from the company’s proprietary antibody-drug conjugate (ADC) technology platforms.
WCG Clinical
MAY 28, 2024
The currently approved CD-19 CAR products are autologous, ex vivo cellular therapies. Recent headlines have highlighted the potential for Chimeric Antigen Receptor (CAR)-based therapies to provide clinical benefits to persons affected by lupus. In these cases B cell depletion is a feature, not a bug.
Drug Discovery World
JUNE 17, 2024
A multispecific antibody candidate for B cell lymphoma preferentially engaged CD47 in presence of co-engagement of CD20 and CD19, in preclinical investigations. One dose of Nutcracker Therapeutics’ NTX-472 in vivo rapidly depleted B cells with no detectable binding to red blood cells.
Drug Discovery World
AUGUST 3, 2022
Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake.
Drug Discovery World
SEPTEMBER 6, 2022
There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. Among these include Zolgensma, Novartis’ gene therapy drug for spinal muscular atrophy (SMA), which made headlines in the UK for its £1.79 billion, compared to $19.9 million price point per dose. Cancer is king .
Expert insights. Personalized for you.
52 
Let's personalize your content